Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin

Autor: Rinaldo Pellicano, Aldo Manca, Alessia Ciancio, Marco Tabone, R. Bonardi, Mario Rizzetto
Rok vydání: 2011
Předmět:
Male
Time Factors
Cost-Benefit Analysis
Hepacivirus
Gastroenterology
Polyethylene Glycols
chemistry.chemical_compound
Liver Function Tests
Recurrence
Pegylated interferon
Chronic Hepatitis C
therapy
genotype 1
short treatment
medicine.diagnostic_test
virus diseases
General Medicine
Hepatitis C
Middle Aged
Viral Load
Recombinant Proteins
Treatment Outcome
Predictive value of tests
Drug Therapy
Combination
Female
Viral load
medicine.drug
Adult
medicine.medical_specialty
Genotype
Antiviral Agents
Drug Administration Schedule
Pharmacotherapy
Predictive Value of Tests
Internal medicine
Ribavirin
medicine
Humans
Rapid Virologic Response
Pharmacology
Dose-Response Relationship
Drug
business.industry
Interferon-alpha
Hepatitis C Antibodies
Hepatitis C
Chronic
medicine.disease
digestive system diseases
chemistry
Immunology
Liver function tests
business
Zdroj: Biomedicine & Pharmacotherapy. 65:303-306
ISSN: 0753-3322
DOI: 10.1016/j.biopha.2011.03.004
Popis: Background In patients with chronic hepatitis C, rapid HCV-RNA clearance under treatment might allow shorter treatment duration without modifying the sustained virological response (SVR) rate. This study evaluated the impact of rapid virological response (RVR) in HCV genotype 1b infection management. Methods In an open-label trial, 180 patients received standard doses of peginterferon alfa-2a plus ribavirin. Those with undetectable serum HCV-RNA at week 6 (RVR) received 24-week short-course treatment; patients with undetectable HCV-RNA at week 12 (early responders [ER]) received 48-week “standard of care” treatment; patients with positive HCV-RNA at week 12 (non-responders [NR]) stopped the treatment. Study end-point was to determine SVR rate at week 24. Results The following responses were observed: 24% RVR, 44% ER, 32% NR. Among RVR subjects, HCV-RNA baseline levels and age were significantly lower (P = 0.038 and 0.035 respectively) than in non-RVR patients. At follow-up, 91% of RVR and 33% of ER patients achieved SVR. Among those with RVR, patients experiencing post-therapy relapse were older than those who achieved a SVR (P = 0.028). Conclusions Chronic HCV-1b patients, achieving RVR with a 24-week treatment regimen, attained excellent SVR rates. In a cost-effective therapeutic approach, all HCV-1b patients eligible for therapy may have a short duration therapy on the basis of RVR.
Databáze: OpenAIRE
Externí odkaz: